Anna Eshoo: “A source of pride of this subcommittee is our history of bipartisan work to advance user fee agreements.”

The PBM Accountability Act will finally shed a light on the opaque drug pricing system.

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

We need more guardrails in place on AI, which is why I introduced the Real Political Ads Act earlier this month.

This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.